BioSpace News Archive

Ecolab Fourth Quarter Reported Diluted Continuing Operations EPS $1.04; Adjusted Diluted Continuing Operations EPS $1.23, -15%; Earnings Show Sequential Improvement From Third Quarter

A survey commissioned by Itamar Medical found that a third of respondents were unaware that treating sleep apnea can significantly reduce the health risks associated with cardiovascular disease, diabetes, and stroke

Corbin Clinical Resources, parent company of Perineologic, is a privately held medical device manufacturer. They have developed and commercialized the PrecisionPoint™ Transperineal Access System, which is the only FDA cleared, CE marked, Class ll medical device for performing freehand transperineal prostate biopsies.

With ZEISS Visioner 1, ZEISS is launching an innovative digital microscope that for the first time enables all-in-one focus in real time thanks to its Micro-mirror Array Lens System (MALS™).

CyberMDX , a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks, today announced that the company has been named a Representative Vendor in the Gartner 2020 Market Guide for Medical Device Security Solutions.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2020, as well as key clinical and corporate developments.

Scientific Bioprocessing, Inc., a subsidiary of publicly-owned Scientific Industries, Inc., announced the launch of its Intelligent, Dynamic Fiber Optic Kit.

Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced that the Company will present at The Microcap Rodeo Winter Wonderland Conference on February 17, 2021 at 2:30pm EST.

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has thus far raised a total of US $1.1 million under the terms of a Series F Preferred Stock Offering.

QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 87.5% of patients in this study have avoided a cystectomy to date